What are the functions and effects of tepotinib? How to use this medicine correctly?

Tepotinib (Tepotinib), as an oral small molecule targeted therapy, has shown significant therapeutic effects in the treatment of non-small cell lung cancer (NSCLC) in recent years, especially for patients carrying MET exon 14 skipping mutations. This drug precisely inhibits the activity of MET receptor tyrosine kinase, thereby effectively blocking the proliferation and metastasis pathways of tumor cells, bringing new treatment hope to lung cancer patients.

So, how exactly does tepotinib work? Its core mechanism is that tepotinib can specifically bind to MET protein, thereby inhibiting the activity of MET receptor tyrosine kinase and blocking the conduction of downstream signaling pathways. This series of effects plays a crucial role in inhibiting the proliferation, migration and survival of tumor cells. Clinical trial data fully show that tepotinib has shown significant efficacy in patients with non-small cell lung cancer carrying MET exon 14 skipping mutations, and can effectively slow down the growth rate of tumors and even significantly reduce the tumor size in some patients. At the same time, the drug also shows good safety, and most patients can tolerate the treatment process smoothly.

So, how to use tepotinib correctly? First, patients must strictly follow the doctor's instructions to ensure the effectiveness and safety of the treatment. Under normal circumstances, adult patients are recommended to take Tepotinib orally once a day, with the recommended dose being 450 mg (i.e. two 225 mg tablets), and it is best to take it with food, which will help the stable absorption and metabolism of the drug in the body.

Patients need to pay close attention to their body's reactions while taking the medication. If any discomfort or side effects occur, such as nausea, diarrhea, fatigue and other symptoms, you should report it to your doctor in time. Doctors will flexibly adjust the medication plan based on the patient's specific conditions, such as appropriately reducing the dose or temporarily discontinuing medication. In addition, patients should undergo regular reexaminations as required by their doctors in order to promptly monitor changes in their condition and the efficacy of the drugs.

It is important to note that tepotinib is only suitable for patients carryingMET exon 14 skipping mutations. Therefore, before using this drug, patients must confirm their MET exon 14 mutation status through genetic testing to ensure the accuracy and effectiveness of the drug.

In summary, tepotinib, as an efficient and safe targeted anti-cancer drug, provides a new treatment option for non-small cell lung cancer patients carryingMET exon 14 skipping mutations. However, its use must strictly follow the doctor's instructions. Patients should pay close attention to their own reactions during the medication and maintain close communication with their doctors to jointly develop a personalized treatment plan.

Reference materials:https://www.nicerx.com/medications/tepmetko/